Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Generics Industry Faces Five Major Challenges, Actavis CEO Says (We're Partly Responsible For One Of Them, He Acknowledges)

Executive Summary

U.S. ANDA makers are ending their silver anniversary year on a glum note

You may also be interested in...

ANDA Filing Free-For-All? Matrix's Stay In Kaletra Case Could Remove Risks Of Submitting Early Dual Certification Generic Drug Applications

Matrix's ability to win a stay of litigation over Kaletra patents - and thus avoid a potential forfeit of its generic exclusivity - suggests a possible strategy for other early ANDA filers

Ranbaxy Transfers Atorvastatin, Tamsulosin Filings To Ohm Labs While Valacyclovir Rakes Big Gains

MUMBAI - Ranbaxy - the Indian affiliate of Daiichi Sankyo - is believed to have transferred its abbreviated new drug application filing for Lipitor to its New Jersey-based Ohm Labs facility, after U.S. FDA imposed import restrictions last summer on two of its biggest manufactuirng facilities in India

Pediatric Exclusivity For Brand Biologics Added In Senate FOB Provision, But Generics Have $1 Bil. In Leverage From CBO Score

The roll-out of the health care reform bill now under debate in the Senate is a good news/bad news event for the generic industry

Related Content





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts